Publication

Article

Oncology Live®

December 2010
Volume11
Issue 12

NCCN Launches Consumer-Friendly Versions

Author(s):

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months.

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months. The not-for-profit alliance of leading cancer centers designed the publications as consumer-friendly translations of the organization’s vaunted clinical practice guidelines for oncologists. The NCCN Guidelines for Patients, which can be downloaded, feature “decision trees” that explain treatment options from initial detection throughout the course of the disease. The information is presented in a step-by-step manner intended to help patients discuss their options with their healthcare team.

The Susan G. Komen for the Cure foundation provided a $160,000 grant to help develop and distribute guidelines for breast cancer. The patient guidelines for lung cancer are named in honor of Dana Reeve, who died of lung cancer in 2006, 7 months after her diagnosis. She is the wife of the late actor Christopher Reeve.

By early 2011, the NCCN plans to release patient guidelines on melanoma, non-Hodgkin lymphoma, and colon and prostate cancers. Eventually, the group plans to produce such guidelines on all major adult cancers, More Info» www.NCCN.com

Related Videos
Ruth M. O’Regan, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.